Curaleaf Caught the Wave: Rescheduling Fueled a Transformative Quarter
Schedule III shift unlocks tax relief, banking, and an import-export future; international growth adds fuel.
CURA.TO · Earnings Call · 2026-05-05
The Regulatory Inflection
Curaleaf Holdings delivered a quarter that marks a genuine turning point. Revenue of $324 million grew 6% year-over-year, beating guidance, while the company swung to a net income of $70 million from a year-ago loss. But the real story is regulatory: the Trump administration's decision to reschedule medical cannabis to Schedule III has unlocked a cascade of benefits that Curaleaf is uniquely positioned to capture.
Two weeks ago, under the direction of President Trump, Acting Attorney General Todd Blanche, formally rescheduled medical cannabis from Schedule I to Schedule III, while simultaneously restarting the broader rescheduling process.
CEO Boris Jordan elaborated: “The practical and financial implications are highly transformative to the industry. First, federal funding for medical research will be allowed... Second, the removal of 280E taxation on medical cannabis expected to be retroactive to at least January 1st, immediately unlocks meaningful balance sheet benefits.” — Boris Jordan, Chairman and Chief Executive Officer · 2026-05-05 Curaleaf's medical business represents 60% of domestic revenue, and the company has already filed applications to register with the DEA, opening the door to banking, credit card acceptance, and even import/export—a adult use rescheduling extension that could reshape the competitive landscape.
The company is not waiting for the adult-use decision to plan. Boris noted in Q&A: “Upon my return from Europe, I plan to spend some time in Washington meeting with the DEA as well as the DOJ to see what the timing could be... I really expect not to be able to do this probably until the end of the year.” — Boris Jordan, Chairman and Chief Executive Officer · 2026-05-05 That timeline, while cautious, signals a concrete path to leveraging domestic cultivation for international supply—a move that could dramatically improve margins given Curaleaf currently produces only 20% of what it sells overseas.
International Strength and Supply Chain Shift
Curaleaf International grew revenue 35% year-over-year, led by Germany and the U.K., with early signs of recovery in Poland. This follows years of heavy investment and positions the company as the largest medical cannabis operator in Europe. The implied $1 billion valuation for the international platform underscores its hidden value. President Rahul Pinto highlighted the domestic strategy: “Our domestic business grew 2% year-over-year. And more importantly, we are seeing clear proof points that our strategy is working.” — Rahul Pinto, President · 2026-05-05 That strategy—customer centricity, operational excellence, and brand building—has already driven 15% transaction growth in Florida.
The potential to use U.S. cultivation to feed international markets is a game-changer. As Boris explained, this would not only avoid significant CapEx but also unlock “meaningful gross margin expansion” — Boris Jordan, Chairman and Chief Executive Officer · 2026-05-05 as they scale. This shift is why the company is reassessing its prior plan to expand international cultivation footprint—rather, it will lean on its domestic assets and award-winning genetics.
The SAFE banking prospects are also buoying sentiment. Boris predicted that Senator Scott would move the bill, potentially before year-end, and that guidance from FinCEN and Treasury could allow regional banks to serve the sector sooner. This would remove friction at the point of sale and improve cash management, another step toward normalization.
Financial and Operational Momentum
Financially, the quarter was robust. Gross margin held at 49%, adjusted EBITDA reached $63 million (20% margin), and the company ended with $106 million cash. The $475 million senior secured note was refinanced into an oversubscribed $500 million facility, a strong vote of confidence. The buyout of the remaining 45% of German subsidiary Four 20 Pharma brings Curaleaf International to 100% ownership, simplifying the structure for potential spin-off or further investment.
A routine tax review released significant reserves, contributing to the net income swing—a one-time gain, but one that reflects the changing regulatory landscape. The company also announced a transition to BDO as auditor, positioning for a potential U.S. exchange uplisting.
Beyond the numbers, the company is executing on product innovation. Briq 2, a next-generation vape, and Dark Heart, an ultra-premium flower, are gaining traction. Domestic wholesale grew 19%, proof that brand building is paying off.
The macro tailwinds are intensifying. The upcoming hemp ban is already driving consumers back to regulated channels, and price compression is beginning to decelerate. As Boris noted, “The macro headwinds that constrained growth over the past 3 years are now beginning to turn into meaningful tailwinds.” — Boris Jordan, Chairman and Chief Executive Officer · 2026-05-05
In prior quarters, the tone was more cautious. In February 2026, Boris acknowledged the persistent pricing pressure: “We continue to see pricing pressure across most markets in the United States.” — Boris Jordan, Chairman and Chief Executive Officer · 2026-02-26 And in August 2025, he emphasized the international growth story but with a watchful eye: “Growth in Germany has been very, very strong.” — Boris Alexis Jordan, Chairman and Chief Executive Officer · 2025-08-06 Today, the narrative has shifted from defense to offense.
What changed? The federal rescheduling unlocked a multi-front catalyst: tax relief, banking access, and an import-export opportunity. With its scale, international footprint, and domestic cultivation network, Curaleaf is arguably the best-positioned MSO to benefit. The next 12 months could see a fundamental re-rating as the industry consolidates and institutional capital finally flows in.